Table 1.
Clinical trials in glioma immunotherapy with TLR agonists
| Diagnosis | TLR target | Agent | Phase | Status | Trial | |
|---|---|---|---|---|---|---|
| GBM | TLR3 | PolyICLC/ APVAC1 vaccine | 1 | Not recruiting | NCT02149225 | |
| AIII, GBM | TLR3 | PolyICLC/IMA950 | 1/2 | Recruiting | NCT01920191 | |
| Recurrent Ped LGG | TLR3 | PolyICLC | 2 | Recruiting | NCT01188096 | |
| Recurrent AII, OII, OAII | TLR3 | PolyICLC/glioma peptide | 0 | Not recruiting | NCT00874861 | |
| Recurrent GBM, AIII, OIII, OAIII | TLR3 | PolyICLC/DC vaccine | 1/2 | Not recruiting | NCT00766753 | |
| AIII, OAIII, GBM | TLR3/TLR7 | PolyICLC/Resiquimod/DC vaccine | 2 | Recruiting | NCT01204684 | |
| Ped pontine glioma, ped HGG, recurrent ped LGG, recurrent ped HGG | TLR3 | PolyICLC/ glioma peptide | – | Recruiting | NCT01130077 | |
| GBM/post operative | TLR3 | PolyICLC/radiation | 2 | Completed | NCT00052715 | |
| AIII, OIII, OAIII | TLR3 | PolyICLC | 2 | Unknown | NCT00058123 | |
| GBM/post operative | TLR3 | PolyICLC/Temozolomide/radiation | 2 | Completed | NCT00262730 | |
| High risk AII, OAII | TLR7 | Imiquimod/Tumor lysate vaccine | 0 | Recruiting | NCT01678352 | |
| Recurrent Ped ependymoma | TLR7 | Imiquimod/glioma peptide | 2 | Recruiting | NCT01795313 | |
| Recurrent GBM, AIII | TLR7 | Imiquimod/DC vaccine/Tumor lysate | 2 | Recruiting | NCT01808820 | |
| GBM | TLR7 | Imiquimod/SL-701 vaccine/Leukine 150 micrograms | 1/2 | Recruiting | NCT02078648 | |
| GBM, AIII, Medulloblastoma, Ependymoma | TLR7 | Imiquimod/DC vaccine(tumor stem cell loaded) | 1 | Completed | NCT01171469 | |
| PedGBM, HGG | TLR7 | Imiquimod/DC vaccine/Tumor lysate | 1 | Recruiting | NCT01902771 | |
| GBM | TLR9 | CpG-ODN | 2 | Completed | NCT00190424 | |
A astrocytoma, O oligodendroglioma, OA oligoastrocytoma, GBM glioblastoma multiforme, ped pediatric, LGG low grade glioma, HGG high grade glioma